logo
ENTITY

Vernalis plc (VER LN)

7
Analysis
Health Care • United Kingdom
Vernalis plc, a research and development stage pharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products for various medical disorders. The company markets Frovatriptan, a selective 5-HT1B/1D receptor agonist for an acute oral treatment of migraine headache and its associated symptoms. The company also has a development and licensing agreement to develop approximately six extended-release liquid formulations of short-acting prescription cough cold products. In addition, it is developing V158866, a fatty acid amide hydrolase inhibitor that is in Phase II proof-of-concept (POC) clinical trial for the treatment of various pain and other CNS disorders; and V81444, an adenosine A2A receptor antagonist, which is in Phase Ib/II POC clinical trial for the treatment of Parkinson?s disease and other neurological disorders. Further, the company is developing AUY922, an intravenous Hsp90 inhibitor for treating a range of cancers in Phase I and Phase II clinical trial; CHR2797, an oral aminopeptidase inhibitor for acute myeloid leukaemia and myelodysplastic syndrome under Phase II trial; V158411 molecule and Servier 1, which are in pre-clinical stage for treating cancer; and RPL554, a novel long-acting inhibitor under Phase II clinical trial for treating inflammatory respiratory diseases. The company has collaborations with Asahi Kasei Pharma; Endo Pharmaceuticals Inc; Genentech Inc; H. Lundbeck A/S; Menarini International Operations Luxembourg SA; Novartis Institute for Biomedical Research Inc; Novartis Pharma AG; Servier Research Group; Taisho Pharmaceutical Co., Ltd.; and Tris Pharma Inc. Vernalis plc was incorporated in 1988 and is headquartered in Winnersh, the United Kingdom.
more
bullish•Vernalis plc
•21 Jun 2018 20:01•Issuer-paid

Vernalis - Termination of coverage

Edison Investment Research is terminating coverage on Vernalis (VER). Please note you should no longer rely on any previous research or estimates...

Logo
Share
bullish•Vernalis plc
•28 Feb 2018 18:15•Issuer-paid

Vernalis - Tuzistra XR downgrade prompts strategic rethink

Vernalis has provided a trading and operational update to its guidance for Tuzistra XR prescriptions for financial year-end 2018. Despite dynamic...

Logo
Share
bullish•Vernalis plc
•22 Nov 2017 19:18•Issuer-paid

Vernalis - Operational initiatives in place, execution is key

Tuzistra XR prescriptions (Rx) grew threefold to ~35k in FY16/17 (2nd year on the market) vs ~12k in FY15/16. Investment into addressing the...

Logo
Share
bullish•Vernalis plc
•19 Jul 2017 19:27•Issuer-paid

Tuzistra XR steady growth in Rx run rate

Vernalis has provided a year-end trading and operational update ahead of its FY17 results due to be announced on 12 September. Total revenues are...

Logo
Share
bullish•Vernalis plc
•24 Apr 2017 15:10•Issuer-paid

FDA issues CCP-07 complete response letter

FDA has issued a complete response letter (CRL) to Vernalis’ CCP-07 NDA following its 20 April PDUFA date, outlining questions that need to be...

Logo
Share
No more insights

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.44.3

x